Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Accured Expenses (2016 - 2025)

Adma Biologics' Change in Accured Expenses history spans 13 years, with the latest figure at $701000.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 338.44% year-over-year to $701000.0; the TTM value through Dec 2025 reached $708000.0, up 161.89%, while the annual FY2025 figure was $708000.0, 161.89% up from the prior year.
  • Change in Accured Expenses reached $701000.0 in Q4 2025 per ADMA's latest filing, up from -$1.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $6.1 million in Q2 2023 to a low of -$5.7 million in Q4 2023.
  • Average Change in Accured Expenses over 5 years is -$75500.0, with a median of -$215292.5 recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: soared 12715.52% in 2021, then crashed 4046.14% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at -$5.3 million in 2021, then skyrocketed by 97.43% to -$136585.0 in 2022, then plummeted by 4046.14% to -$5.7 million in 2023, then surged by 94.81% to -$294000.0 in 2024, then soared by 338.44% to $701000.0 in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Change in Accured Expenses are $701000.0 (Q4 2025), -$1.0 million (Q3 2025), and $3.4 million (Q2 2025).